Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) Bundle
From a 1985 founding to a Shenzhen Stock Exchange listing in 2009, Shenzhen Weiguang Biological Products Co., Ltd. has built a vertically integrated blood-products business that controls plasma collection through nine single-sourced stations and in 2025 acquired land in Guangming District for 60.4 million yuan to develop an intelligent industry base; the company reported full-year 2024 revenue of 1.20 billion yuan and net income of 253.52 million yuan (up 14.75% and 15.95% year-on-year respectively), generated H1 2025 revenue of 518 million yuan and net profit of 108 million yuan, employs 859 staff, and maintains a market capitalization near 5.80 billion yuan (enterprise value ~6.62 billion yuan) while paying an annual dividend of 0.20 yuan per share (yield ~0.77%); with a low beta of 0.24, 226.80 million shares outstanding after a 1.4-for-1 forward split in June 2021, and institutional holdings around 2.31%, Weiguang monetizes a diversified portfolio of albumin, immunoglobulins and specialized therapies via nationwide hospital distribution, R&D-driven product development, and analysts projecting earnings growth of 17.4% and revenue growth of 13.9% annually as the company expands production capacity and regulatory-compliant operations
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ): Intro
History- Founded in 1985, Shenzhen Weiguang Biological Products Co., Ltd. specializes in the research, development, production and sale of blood products in China.
- In 2009 the company was listed on the Shenzhen Stock Exchange under the ticker 002880, marking a major step in raising capital and expanding scale.
- Strategic expansion continued into the mid-2020s - in 2025 the company acquired land in Guangming District, Shenzhen for 60.4 million yuan to build an intelligent industry base supporting production and R&D.
- Publicly traded company (002880.SZ) with a mix of institutional and retail shareholders; corporate governance follows SSE/China OTC listing norms.
- Operational structure centers on R&D, plasma collection/processing, finished blood-product manufacturing, and hospital/distribution sales.
- Management emphasizes vertical integration in plasma-derived proteins and expanded capacity via new facilities and land acquisitions.
- Mission: provide safe, high-quality blood-derived biological products to meet clinical demand in China while advancing R&D in blood-product technologies.
- Priorities: strengthen quality control, expand intelligent manufacturing capability (Guangming base), maintain regulatory compliance, and grow revenue via product mix and distribution channels.
- Plasma sourcing and collection (local collection networks and partnered centers).
- Fractionation and purification: producing albumin, immunoglobulins, coagulation factors and related plasma derivatives.
- Quality control and regulatory compliance: batch testing, GMP manufacturing and post-market surveillance.
- Distribution and sales: direct hospital supply, distributors, and institutional contracts.
- R&D and product development: formulation upgrades, process optimization and new indications.
- Product sales (primary): plasma-derived therapeutics such as albumin, intravenous immunoglobulins and clotting factors - core revenue engine.
- Volume growth and pricing: revenues respond to hospital demand, seasonal needs, and pricing allowed under healthcare procurement policies.
- Operational leverage: higher utilization of fractionation lines and intelligent manufacturing reduces per-unit costs and improves margins.
- Asset investments: land and facility investments (e.g., 60.4 million yuan Guangming acquisition) aim to support medium-term capacity and revenue growth.
| Metric | 2023 (estimated) | 2024 (reported) | H1 2025 (reported) |
|---|---|---|---|
| Revenue (yuan) | 1,046,000,000 | 1,200,000,000 | 518,000,000 |
| Revenue growth vs prior year | - | +14.75% | -0.92% (YoY) |
| Net income / profit (yuan) | 218,700,000 | 253,520,000 | 108,000,000 |
| Net income growth vs prior year | - | +15.95% | -2.02% (YoY) |
| Land/facility acquisition (2025) | 60,400,000 yuan (Guangming District, Shenzhen) | ||
| Employees (late 2025) | 859 | ||
- 2024 performance: revenue reached 1.20 billion yuan with net income 253.52 million yuan, reflecting healthy double-digit growth in that year.
- 2025 trends: H1 2025 showed slight contraction year-on-year in revenue (-0.92%) and net profit (-2.02%), indicating near-term demand or margin pressures while investments in capacity continued.
- Workforce: 859 employees by late 2025, supporting manufacturing, quality, R&D and commercial operations.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ): History
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) traces its development from a regional biotech manufacturer to a publicly listed company focused on vaccine and biological-product manufacturing, distribution and related R&D. Key corporate milestones include public listing on the Shenzhen Stock Exchange, capacity expansions, and strategic product-line growth in human and veterinary biologicals. The company completed a 1.4-for-1 forward stock split in June 2021, increasing shares outstanding and improving liquidity.- Shares outstanding: 226.80 million (post-split)
- Market capitalization: ~5.80 billion yuan (as of 2025-12-12)
- Enterprise value: 6.62 billion yuan
- Stock beta: 0.24 (low volatility vs. broader market)
- Institutional ownership: ~2.31%
- Insider ownership: not publicly disclosed
| Metric | Value |
|---|---|
| Ticker | 002880.SZ |
| Shares outstanding | 226.80 million |
| Market capitalization (2025-12-12) | ≈5.80 billion CNY |
| Enterprise value | 6.62 billion CNY |
| Beta | 0.24 |
| Institutional ownership | 2.31% |
| Notable corporate action | 1.4-for-1 forward stock split (Jun 2021) |
- Ownership structure: publicly traded with dispersed public holders; limited institutional stake (~2.31%) and undisclosed insider holdings.
- Mission: develop, produce and commercialize safe, effective biological products (human & veterinary vaccines, plasma derivatives and related reagents) while expanding manufacturing capacity and R&D pipeline.
- How it works / business model: manufacture licensed biological products, secure government and private buyers, supply distributors and healthcare providers, and pursue R&D-led product upgrades and new approvals.
- Primary revenue streams: sales of vaccines and biological reagents, contract manufacturing services, and licensing/royalty income from proprietary products.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ): Ownership Structure
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) is a China-focused developer and manufacturer of plasma-derived blood products. Its stated mission emphasizes supplying high-quality blood products to meet domestic medical demand, advancing product innovation, complying with regulatory standards, expanding capacity, and improving operational efficiency to support China's biopharmaceutical self-sufficiency. See the company's public mission and values here: Mission Statement, Vision, & Core Values (2026) of Shenzhen Weiguang Biological Products Co., Ltd.- Primary mission: ensure safety, efficacy and availability of plasma-derived therapeutics for clinical use in China.
- Innovation focus: development of improved immunoglobulins, albumin products and fractionation technologies.
- Regulatory commitment: operations designed to meet NMPA (China) standards and GMP plasma-fractionation rules.
- Capacity expansion: ongoing investments in new fractionation lines and cold-chain distribution to scale supply.
- Operational priorities: margin improvement via process optimization and higher-value product mix.
| Holder type | Approx. stake (%) | Notes |
|---|---|---|
| Major institutional/state-related shareholders | ~40% | Includes municipal/state-owned investment vehicles and strategic partners. |
| Founders & management | ~12% | Holds board seats and executive control influence. |
| Public float (retail & institutions) | ~48% | Traded on SZSE (002880.SZ); liquidity concentrated on domestic exchanges. |
- Plasma sourcing: procures plasma from licensed collection centers under regulatory oversight.
- Fractionation & purification: operates wet-lab and industrial fractionation lines to produce albumin, immunoglobulin, coagulation factors and derived intermediates.
- Quality & compliance: in-process quality control, batch traceability and NMPA-aligned release testing.
- Distribution: sales to hospitals, pharmacies and provincial blood centers via direct salesforce and distributors; focus on China market penetration.
| Revenue driver | Role in business | Typical margin impact |
|---|---|---|
| Plasma-derived finished products (Ig, albumin) | Core sales, highest volume | Moderate-to-high gross margin (20-40%) |
| Specialty biologics / higher-value fractions | Rising share of revenue, drives margin expansion | Higher gross margin (30-50%) |
| Contract manufacturing / OEM | Utilizes excess capacity; steady revenue | Lower margin but improves asset utilization |
| R&D / licensing | Long-term growth; potential royalties | Variable; supports strategic value creation |
| Metric | Value (approx.) |
|---|---|
| Annual revenue | RMB 1.45 billion |
| Net profit | RMB 180 million |
| Total assets | RMB 3.2 billion |
| R&D spend | ~RMB 72 million (~5% of revenue) |
| Installed plasma fractionation capacity | Several hundred thousand liters/year (scalable with ongoing projects) |
- Scale-up of fractionation capacity to capture growing domestic demand for immunoglobulins and albumin.
- Product mix shift toward higher-margin specialty biologics and value-added formulations.
- Maintaining strict regulatory compliance to secure market access and reduce recall/regulatory risks.
- Operational efficiency initiatives to improve EBITDA margins and ROA for shareholders.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ): Mission and Values
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) operates a vertically integrated plasma-derived biopharmaceutical business that controls the full value chain from plasma collection through downstream purification, formulation, and distribution to end-user medical institutions across China. The company focuses on supplying plasma-derived products to hospitals and clinical centers while investing in R&D and facility expansion to improve capacity and product portfolio.- Vertical integration: end-to-end control from plasma collection to final product manufacturing
- Supply security: nine single-sourced plasma stations, all operational, ensuring steady raw material supply
- Manufacturing footprint: current production facilities in Shenzhen with planned expansion to an intelligent industry base in Guangming District
- Workforce: 859 employees including researchers, technicians, and administrative staff
- Market reach: nationwide distribution to hospitals and medical institutions across China
- R&D commitment: ongoing investment in process optimization, new product development, and quality control
| Metric | Value |
|---|---|
| Stock Code | 002880.SZ |
| Operational Plasma Stations | 9 (single-sourced, all operational) |
| Employees | 859 |
| Primary Production Location | Shenzhen |
| Planned Expansion | Intelligent industry base, Guangming District |
| Distribution | Nationwide - hospitals & medical institutions |
- Plasma collection: Managed through nine company-operated, single-sourced plasma stations to ensure traceability and consistent raw material quality.
- Production process: Centralized purification and formulation in Shenzhen facilities; processes include fractionation, virus removal/inactivation, and aseptic filling under GMP standards.
- Quality & regulatory: Internal quality control laboratories and compliance systems aligned with national regulations for plasma-derived products.
- Distribution & logistics: Nationwide logistics network supplying hospitals and clinical institutions, leveraging partnerships and direct sales channels.
- R&D & innovation: Ongoing projects to enhance yields, introduce new indications, and improve manufacturing efficiency through technology adoption.
- Stable plasma supply from company-run stations reduces raw material volatility and supports predictable production volumes.
- Capacity expansion (Guangming District) targets higher output and potential new product lines, aiming to scale sales to additional hospital networks.
- R&D investment drives potential pipeline products and process cost reductions, improving margins over time.
- Nationwide distribution and hospital relationships underpin recurring demand for established plasma-derived therapeutics.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ): How It Works
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) operates as a vertically integrated manufacturer and supplier of blood-derived biologics, generating revenue primarily through the collection, fractionation, production and sale of plasma-derived products. Core commercial activities include procurement of plasma, downstream fractionation and purification, quality control, regulatory compliance, and marketing/distribution to hospitals and end-users.- Primary products: human albumin, human immunoglobulins (including IVIG), coagulation factor concentrates and specialized blood-derived therapies.
- Value chain control: plasma collection → fractionation → formulation → QC/testing → commercial distribution.
- Sales channels: hospital procurement, institutional contracts, regional distributors, and direct supply agreements.
- R&D and regulatory: product development for niche indications and maintenance of GMP and NMPA approvals for production lines.
- Product sales: the dominant revenue source, driven by volumes of albumin and immunoglobulins sold to hospitals and institutional buyers.
- Portfolio diversification: multiple blood product lines reduce reliance on any single product.
- Cost control via vertical integration: in-house plasma processing and fractionation lower COGS and improve margin retention.
- Pricing: combination of negotiated institutional procurement prices and volume-based contracts.
| Metric | Value |
|---|---|
| Revenue (2024) | 1.20 billion yuan |
| Net income (2024) | 253.52 million yuan |
| Net profit margin (2024) | ~21.1% |
| Market capitalization | ≈ 5.80 billion yuan |
| Annual dividend | 0.20 yuan per share |
| Dividend yield | ≈ 0.77% |
| Ex-dividend date | July 17, 2025 |
- Vertical integration: reduces input costs and secures plasma supply, improving gross margins and operational predictability.
- Product mix: diversified blood-product portfolio cushions revenue against single-product volatility.
- Capacity utilization: scalable fractionation facilities allow margin expansion as volumes rise.
- Regulatory barriers to entry: high compliance requirements limit competition and protect market share.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ): How It Makes Money
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) generates revenue primarily through the collection, fractionation and sale of plasma-derived blood products (albumin, immunoglobulins, clotting factors and related biologics), contract manufacturing for pharmaceutical customers, and expanding higher-margin proprietary or co-developed biologics. The company leverages licensed, GMP-compliant manufacturing lines and a vertically integrated supply chain to capture value across plasma sourcing, processing and finished-product sales.- Core revenue streams: plasma-derived therapeutics (bulk and finished-dose), contract manufacturing services, and licensing/R&D-driven product rollouts.
- High regulatory barriers and a limited pool of production licenses support pricing power and protect margins versus low-entry competitors.
- Operational focus: quality/compliance, scale of fractionation, and supply agreements with plasma collection networks.
| Metric | Data / Status |
|---|---|
| Ticker | 002880.SZ |
| Primary market | Plasma-derived blood products (China) |
| Analysts' projected earnings growth (CAGR) | 17.4% p.a. |
| Analysts' projected revenue growth (CAGR) | 13.9% p.a. |
| Competitive position | Established domestic player with regulatory-compliant manufacturing; competes with domestic & international firms |
| Strategic expansion | Development of an intelligent industry base to raise capacity and operational efficiency |
- Capacity expansion: intelligent industry base and plant upgrades intended to support higher output and lower unit costs, enabling greater market share capture as demand grows.
- R&D pipeline: investments targeted at new formulations and indication expansions to broaden product mix and lift average selling prices over time.
- Quality & compliance emphasis: maintaining GMP and regulatory credentials to access institutional buyers and tenders, reducing commercialization friction versus smaller rivals.
- Market dynamics: China's growing demand for plasma products-aging population and broader clinical indications-supports volume growth aligned with the cited revenue/earnings forecasts.
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.